Harrow Inc. Set for H.C. Wainwright Conference Participation
Harrow Inc. Ready to Shine at H.C. Wainwright Conference
Harrow, a prominent eyecare pharmaceutical company, has exciting news as it prepares to participate in the H.C. Wainwright 5th Annual Ophthalmology Conference. This year, the event will be held virtually, allowing a wider audience to engage with the discussions and insights shared by leading experts in the field.
Engagement of Key Executives
At the conference, Harrow's Chief Executive Officer, Mark L. Baum, along with Chief Financial Officer Andrew Boll, will be hosting a fireside chat. This discussion is scheduled for Wednesday at 8:30 a.m. Eastern Time. It's a fantastic opportunity for attendees to hear directly from the company's leadership regarding their innovative approaches and strategies within the eyecare market.
Panel Discussion on Novel Treatments
Additionally, Mark L. Baum will feature in a panel discussion focused on "Novel Treatments for Front-of-the-Eye Indications." Slated for 1 p.m. Eastern Time, this panel is expected to shed light on the latest advancements in eyecare treatments, showcasing Harrow’s commitment to innovation in the industry.
Live Webcast Information
The fireside chat and panel discussion will be available via live webcast, ensuring that both industry professionals and interested individuals can access the conversation. Interested participants can find the webcast link on Harrow's official website, where a replay will also be accessible for about 90 days following the event.
About Harrow
Harrow, Inc. (NASDAQ: HROW) is dedicated to the development and commercialization of innovative ophthalmic pharmaceutical products. Their mission revolves around making eyecare accessible and affordable, thus helping professionals preserve vision for millions of patients each year. With a robust portfolio, Harrow is at the forefront of developing therapies that respond to the evolving needs within the eyecare community.
Contact Information
For further inquiries, you can reach out to Mike Biega, Vice President of Investor Relations and Communications, at mbiega@harrowinc.com or by phone at 617-913-8890.
Frequently Asked Questions
What is the H.C. Wainwright Ophthalmology Conference?
The H.C. Wainwright Ophthalmology Conference is an annual event that brings together leading professionals in the eyecare field to discuss the latest advancements and innovations.
How can I access the webcast for the conference?
The webcast will be available on Harrow's official website, with a replay accessible for approximately 90 days after the event.
Who are the key speakers from Harrow at the event?
Mark L. Baum, CEO, and Andrew Boll, CFO, are the key speakers representing Harrow at this conference.
What topics will be discussed at the panel?
The panel will focus on "Novel Treatments for Front-of-the-Eye Indications," discussing advancements in therapies for various eye conditions.
What is Harrow’s mission as a company?
Harrow aims to provide innovative ophthalmic pharmaceutical products to make eyecare more accessible and affordable for patients around the globe.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.